Advaxis, Inc. (NASDAQ: ADXS)
Advaxis, Inc. (ADXS), a clinical stage biopharmaceutical company, yesterday announced that it received the “Medical Visionary Angel Award” from the Farrach Fawcett Foundation. The company also announced plans to initiate the Phase 2 FAWCETT study of their drug axalimogene filolisbac (ADXS-HPV) in metastatic anal cancer this fall.
Advaxis, Inc. CEO’s Comments
“We would like to thank the Farrah Fawcett Foundation for this honor,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “While there is still so much work to be done in this space, we are unwavering in our commitment to bring new treatments to market in anal cancer and other underserved HPV-associated cancers.” Globe Newswire
ADXS Technical Analysis
On Friday, ADXS gapped up in price to $16.03 up from Thursday’s close of $15.96. This is not much of a gap up as the stock made the bulk of its move yesterday when it opened at $13.88 and closed at $15.96 a 15% increase in price. I would be looking for a continuation of the run up. The stock has shown the ability to make big moves in a short period of time in the past. Taking a look at the daily chart we can see on May 27 the stock traded at a low of $22.15 and moved all the way to its 52 week high of $30.13 on June 8 a 36% increase in price. Another example is back on Aug 13 when the stock opened at $16.78 and reached a high of $18.48 a 10% increase in price. As we can see the stock is very volatile which is not uncommon of a biopharmaceutical company. The stock did reach a pre market high of $16.67 which means it gave back $0.64 at the open equivalent to 4%. For trading purposes my entry point would be $16.10 looking for a run to the pre market high of $16.67. My stop loss would be the whole number $16.00 fearing anything below that and the stock may give back some of the profits from yesterday.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate designed to target the PSA antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate for the treatment of Her2 expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has a clinical trial collaboration with MedImmune, LLC to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV, a cancer immunotherapy vaccine to treat patients with cervical cancer, and HPV-associated head and neck cancer. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey. Yahoo Finance